{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116413","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.411791+00:00","generated_at":"2026-05-30T02:03:45.013919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Replimune reports Q2 FY2025 net loss $53.1M; BLA for RP1 in melanoma on track before year-end","bullets":["Completed pre-BLA meeting with FDA; BLA submission for RP1+nivolumab in anti-PD1 failed melanoma via accelerated approval path on track by end of 2024.","IGNYTE primary analysis: 33.6% ORR at 12 months by modified RECIST 1.1; median DOR from response initiation 21.6 months.","Cash, cash equivalents and short-term investments $432.1M as of Sep 30, 2024; funding operations into H2 2026.","R&D expenses $43.4M, down from $49.1M; net loss $53.1M, improved from $60.0M YoY.","RP2 in uveal melanoma: registration-directed trial with first patient enrollment expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116413","json":"https://secwatch.observer/filing/0001104659-24-116413.json","markdown":"https://secwatch.observer/filing/0001104659-24-116413.md","text":"https://secwatch.observer/filing/0001104659-24-116413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/0001104659-24-116413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/tm2428095d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:03:45.013919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}